U.S. Markets closed
  • S&P 500

    3,855.36
    +13.89 (+0.36%)
     
  • Dow 30

    30,960.00
    -36.98 (-0.12%)
     
  • Nasdaq

    13,635.99
    +92.93 (+0.69%)
     
  • Russell 2000

    2,163.27
    -5.49 (-0.25%)
     
  • Crude Oil

    52.85
    +0.08 (+0.15%)
     
  • Gold

    1,853.00
    -2.20 (-0.12%)
     
  • Silver

    25.34
    -0.14 (-0.55%)
     
  • EUR/USD

    1.2142
    -0.0003 (-0.0243%)
     
  • 10-Yr Bond

    1.0400
    -0.0510 (-4.67%)
     
  • Vix

    23.19
    +1.28 (+5.84%)
     
  • GBP/USD

    1.3671
    -0.0004 (-0.0301%)
     
  • USD/JPY

    103.7650
    +0.0090 (+0.0087%)
     
  • BTC-USD

    32,556.35
    -28.47 (-0.09%)
     
  • CMC Crypto 200

    657.51
    -19.39 (-2.86%)
     
  • FTSE 100

    6,638.85
    -56.22 (-0.84%)
     
  • Nikkei 225

    28,693.11
    -129.18 (-0.45%)
     

Kindred Biosciences'(NASDAQ:KIN) Share Price Is Down 51% Over The Past Three Years.

Simply Wall St
·2 min read

Kindred Biosciences, Inc. (NASDAQ:KIN) shareholders should be happy to see the share price up 16% in the last month. But over the last three years we've seen a quite serious decline. Indeed, the share price is down a tragic 51% in the last three years. Some might say the recent bounce is to be expected after such a bad drop. Perhaps the company has turned over a new leaf.

Check out our latest analysis for Kindred Biosciences

Kindred Biosciences isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

This free interactive report on Kindred Biosciences' balance sheet strength is a great place to start, if you want to investigate the stock further.

A Different Perspective

Investors in Kindred Biosciences had a tough year, with a total loss of 45%, against a market gain of about 23%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 6% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For example, we've discovered 2 warning signs for Kindred Biosciences that you should be aware of before investing here.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.